Research Guides

CJC-1295 and Ipamorelin: What the Blend Is

By UK Peptide Lab Research Team•16 November 2026•7 min read
CJC-1295 and Ipamorelin: What the Blend Is · research peptide

Key Takeaways

  • CJC-1295 (without DAC) is a 29 amino acid growth-hormone-releasing-hormone analogue, and ipamorelin is a five amino acid ghrelin-receptor agonist.
  • They act on different receptors, GHRH-R and GHS-R1a, both found on pituitary somatotroph cells.
  • The blend holds both in one vial at a fixed 1:1 mass ratio, which is not a 1:1 ratio of molecules.
  • No controlled study of this specific blend has been published. It is sold here for in-vitro laboratory research only.

What is CJC-1295 Ipamorelin?

CJC-1295 Ipamorelin, also written CJC1295/ipamorelin, is a research vial holding two separate peptides lyophilised together. CJC-1295 without DAC (also called modified GRF 1-29) is a 29 amino acid analogue of growth-hormone-releasing hormone. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, a selective agonist of the ghrelin receptor. It is a research compound, not a licensed medicine. UK Peptide Lab supplies the CJC-1295 + Ipamorelin 5+5mg blend as lyophilised powder for in-vitro laboratory research only.

The two peptides, one at a time

CJC-1295 without DAC carries four substitutions compared with native GHRH(1-29): D-Ala2, Gln8, Ala15 and Leu27. It acts at the GHRH receptor and has a molecular weight of 3367.9 g/mol. Ipamorelin acts at GHS-R1a, the ghrelin receptor cloned by Howard and colleagues (Science, 1996), and has a molecular weight of 711.85 g/mol. Raun and colleagues (European Journal of Endocrinology, 1998) described it as the first selective growth hormone secretagogue, because in their animal work it released growth hormone without the significant rise in ACTH and cortisol seen with earlier compounds of its class.

Why the two are studied together

GHRH-R and GHS-R1a are different receptors, but both are on the pituitary somatotroph cell. Bowers and colleagues (J Clin Endocrinol Metab, 1990) reported that a growth-hormone-releasing peptide acts synergistically with GHRH, and that synergy is the basis for pairing a GHRH analogue with a ghrelin-receptor agonist in research designs. The two inputs can then be applied together in one preparation.

A note on DAC

DAC (drug affinity complex) is a chemical addition that extends the half-life of CJC-1295. Teichman and colleagues (J Clin Endocrinol Metab, 2006) studied the DAC form in healthy adults, and that paper is the main clinical reference for the compound. The blend sold here uses the form without DAC, so that paper does not describe it. The CJC-1295 with and without DAC comparison covers the difference.

Blend or separate vials

The blend contains both peptides in one vial at a fixed 1:1 mass ratio, with a certificate for the listed batch. Separate CJC-1295 and ipamorelin vials are also listed. No controlled study of this specific blend has been published, so the evidence comes from each peptide's own literature. The CJC-1295 vs ipamorelin comparison sets the two side by side.

Further research information

The two peptides are listed together in one research vial. The reconstitution guide is a separate resource; this page does not provide preparation instructions. Check the batch certificate linked from each product page for material-specific details.

Sourcing CJC-1295 Ipamorelin in the UK

UK Peptide Lab lists the CJC-1295 + Ipamorelin 5+5mg blend and a 10+10mg vial, each with its own batch certificate linked on the product page. For in-vitro laboratory research use only, not for human consumption.

Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.

Frequently Asked Questions

What is CJC-1295 Ipamorelin?

It is a research vial holding two separate peptides lyophilised together: CJC-1295 without DAC, a 29 amino acid growth-hormone-releasing-hormone (GHRH) analogue, and ipamorelin, a five amino acid selective agonist of the ghrelin receptor. It is a research compound, not a licensed medicine.

What is the difference between CJC-1295 and ipamorelin?

They are different molecules acting at different receptors. CJC-1295 acts at the GHRH receptor and ipamorelin acts at the ghrelin receptor GHS-R1a. Both receptors sit on the pituitary somatotroph, which is why the two are studied together.

What does CJC-1295 with DAC mean?

DAC is a drug affinity complex added to extend half-life. The blend sold here uses CJC-1295 without DAC (modified GRF 1-29). The main published clinical pharmacology study of CJC-1295, Teichman et al. (2006), used the DAC form, so it does not describe this blend.

Is a 1:1 mass ratio the same as a 1:1 molar ratio?

No. At 3367.9 g/mol for CJC-1295 and 711.85 g/mol for ipamorelin, 5mg of each is about 1.5 µmol of CJC-1295 and 7.0 µmol of ipamorelin, roughly 1 to 4.7 by moles.

Where are the blend's batch certificates?

Each listed size has a batch certificate linked from its product page. Check the certificate for the identity of the listed material.

References

  1. [1] Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998). View →
  2. [2] Howard et al., growth hormone secretagogue receptor. Science (1996). View →
  3. [3] Teichman et al., CJC-1295 clinical pharmacology. J Clin Endocrinol Metab (2006). View →